Estenosis aortica degenerativa: punto de vista del clĂnico Dr Pilar Tornos Hospital Vall d’Hebron. Barcelona Congreso de la SEC. Valencia 2010
Estenosis aortica degenerativa Unidad de valvulopatías: Lineas de investigación clínica
•
Click to edit Master text styles
– Second level – Third level • Fourth level – Fifth level
• Epidemiologia • Dificultades en la valoracion de la severidad • Tratamiento
Valvulopatías y edad
EA
EA Nkomo V et al. Lancet 2006
Age (years)
≥ 70 years (%)
≥1 comorbidity (%)
AS
69±12
56
36
AR
58±16
25
26
MS
58±13
18
22
MR
65±14
44
42
EURO HEART SURVEY Iung et al. Eur Heart J 2003
Epidemiologia: Que datos tenemos? - Pocos estudios han valorado los patrones de esclerosis/estenosis aórtica a nivel poblacional. - El mas reciente se llevó a cabo hace mas de una década - Ninguno está realizado en el área mediterránea - La mayoría no utilizaban ecografia con segundo harmónico - Solo 2 de ellos se centraban especificamente en >64 años - Prevalencia variable para esclerosis (18.2%-53%) y estenosis (1.3%-4.8%) - En relación a los factores de riesgo asociados: - Estercha correlacion esclerosis/estenosis y edad - Asociación plausible con el género - TProbable asociación con factores de riesgo de arteriosclerosis(LDL-c, Total-c, Lp(a), Dm…) - Podría haber asociación con factores constitucionales (BMI)
PEEADE STUDY Study sample selection Reference population: All population ≥ 65 years included in the list of nine Primary Care facilities of Barcelona metropolitan area (54,594 subjects ≥ 65; 16.5% of the total Barcelona population ≥ 65 years) Sample size: - Expected ASt prevalence in ≥ 65 years: 3% - Absolute precision: 1% (relative precision 33%) - 95% CI; N=1,118 Sampling: Age-stratified according with the Barcelona demographics census (3 strata: 65-74, 75-84, ≥ 85) Screening process: 2,800 people were randomly selected from the Primare Care list (eligible population). They were consecutively contacted by phone call and invited to participate until completing the study sample (1,118 cases).
PEEADE STUDY Results: Screening process
2,562 phone calls N=1,029 (40%) not localized 1,533 Invited to participate N=391 (25.5%) refused 1,142 agreed to participate N=6 (0.05%) with aortic prosthesis 1,136 underwent echocardiography N=155 (13.6%) with not high quality echo view for fine ASc assessment N=981
PEEADE STUDY Results: ASc and ASt prevalence 65-74 y (n=454; 46.3%)
75-84 y >84 y (n=409; 41.7%) (n=118; 12%)
GLOBAL (n = 981)
Aortic Sclerosis Mild to moderate Moderate to severe Any
Aortic Stenosis
1. Standardized Spain 2009
105 (23.1%)
140 (34.2%)
47 (39.8%)
292 (29.8%) 29.4%1 28.9%2
25 (5.5%)
73 (17.8%)
39 (33.1%)
137 (14%) 13.7%1 12.9%2
130 (28.6%)
213 (51.1%)
86 (72.9%)
429 (43.7%) 43%1 41.8%2
3 (0.7%)
21 (5.5%)
10 (8.5%)
34 (3.5%) 3.3%1 3.1%2
2. Standardized Europe 2008
Valoracion de la severidad de la EA • Click to edit Master text styles – Second level – Third level • Fourth level – Fifth level
Baumgartner H et al Eur J Echo, 2009
• Click to edit Master – Second level
•
Click to edit Master text styles
•
Click to edit Master text styles
– Second level
– Second level
– Third level
– Third level
• Fourth level – Fifth level
• Fourth level – Fifth level
•
Velocidad: 4.29 m/sec Gradiente medio 44 mmHg Area 0.75 cm2
Click to edit Master text styles
– Second level – Third level • Fourth level – Fifth level
Estenosis aórtica severa
• Click to edit Maste
Dificultades en la correcta catalogación de la severidad • Mala función ventricular
test dobutamina
• Función ventricular conservada, bajo gradiente y área reducida
Considerar los posibles problemas en el cálculo del área
Gradm: 26 mmHg
GC: 4.13 L/min
FÓRMULA DE GORLIN
ECOCARDIOGRAMA EN EL LABORATORIO DE HEMODINÁMICA
ECUACIÓN CONTINUIDAD: Área valvular aórtica: 0.66 cm2 Velocidad 3.3 m/S y gradiente medio 24 mm HG
BASAL TA 205/65, 59 x min Gradm: 26 mmHg
GC: 4.13 L/min
POST-NITROPRUSIATO 105/75, 74 x min Gradm: 32 mmHg
GC: 4.57 L/min
ECOCARDIOGRAMA BASAL
AVA 0.66
ECOCARDIOGRAMA POST-NITROPRUSIATO
AVA 0.9
Management of Severe Aortic Stenosis
Severe AS (< 1 cm² or < 0.6 cm²/m² BSA) Symptoms No
Yes
LV EF < 50%
No Yes
Markedly calcified valve and increase in peak jet velocity ≥ 0.3 m/sec within 1 year
No Yes
Patient physically active
Yes
Exercise test No Re-evaluate in 6 to 12 months or when symptoms occur
Normal
Abnormal Surgery
Haga clic para modificar el estilo GuidelinesSegundo ESC,2007 nivel ● Tercer nivel
• “Age is not a contraindication to surgery, with several series showing outcomes similar to age-matched normal subjects in the very elderly” Guidelines, 2006
ACC/AHA
• “Age per se should not be considered a contraindication for surgery. Decisions sould be made on an individual basis, taking into account patients’s wishes and cardiac and non cardiac factors. In this population the need for an emergency operation, or, at the other end of the clinical spectrum, vey early intervention at an asymptomatic stage, should be avoided” Guidelines, 2007
European
•
Click to edit Master text st
– Second lev
Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Bernard Iung, Agnès Cachier, Gabriel Baron, David Messika-Zeitoun, François Delahaye, Pilar Tornos, Christa Gohlke-Bärwolf, Eric Boersma, Philippe Ravaud and Alec Vahanian
Eur Heart J 2005 26:2714-2720
REASONS THAT AORTIC VALVE REPLACEMENT WAS NOT PERFORMED AS during 2005 155 patients with severe AS In 75 surery was not performed 22 asymptomatic 53 symptomatic
Calculated operative risk was 11-13% Only 35% evaluated by a surgeon
Symptomatic pts (n = 53) Prohibitive comorbidities
30 (57%)
Symptoms felt due to another etiology
11 (21%)
Died before surgery Presented in cardiogenic shock
2 (4%)
Planned elective surgery
2 (4%)
Subvalvular obstruction
3 (6%)
Aortic stenosis unrecognized
3 (6%)
Patient declined intervention
2 (4%)
Bach, D. S. et al. J Am Coll Cardiol 2007;50:2018-2019
Cirugía de recambio valvular por estenosis aórtica severa en mayores de 80 años. Experiencia de un centro en una serie de pacientes consecutivos David Calvo et al Rev Esp Cardiol 2007; 60: 720 - 726 137 pacientes con EA severa edades entre 80 y 87 años, media 81 MORTALIDAD QUIRURGICA: 3.8%
33 se rechazó
Haga clic para modificar el estilo de cirugía (24%) Segundo nivel ● Tercer nivel ● Cuarto nivel
> 30% de pacientes con EA sintomรกtica no se operan.
No Surgery Surgery
1. Bouma et al. To operate or not on elderly patients with aortic stenosis: the decision and its consequences. Heart 1999; 82: 143-148 2. Iung et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. European Heart Journal 2003; 24: 1231- 1243 3. Pellikka et al. Outcome of 622 Adults with Asymptomatic, Hemodynamically Significant Aortic Stenosis During Prolonged Follow-Up. Circulation 2005 4. Charlson et al. Decision-making and outcomes in severe symptomatic aortic stenosis. J Heart Valve Dis 2006; 15: 312-321
La cirugía no se realiza en un número considerable de pacientes • Las razones para no enviar los pacientes a cirugía pueden deberse a desconocimiento de los resultados o a la dificultad en la estimación del riesgo quirúrgico • Las razones por las que los equipos quirúrgicos rechazan a los pacientes tampoco son uniformes
•
Click to edit Master text
– Second le
Supervivencia de pacientes con EA no operada
Bach, D. S. et al. J Am Coll Cardiol 2007;50:2018-2019
Supervivencia en octogenarios con EAo
• Click to edit Master text styles – Second level – Third level • Fourth level – Fifth level
Nkomo V et al. Lancet 2006
Nueva modalidad terapéutica: TAVI
• Click to edit Master text styles – Second level – Third level • Fourth level – Fifth level
NEJM, 2010
• Click to edit Master – Second level
2010.Manejo apropiado de la EA • Reconocimiento de la lesión • Correcta catalogación de la severidad • Aconsejar cirugía con precocidad, según las indicaciones de las Guias • En caso de paciente de alto riesgo quirúrgico considerar Implantación de Protesis Transcateter •
Click to edit Master text s
– Second le
Management of Severe Aortic Stenosis
Severe AS (< 1 cm² or < 0.6 cm²/m² BSA) Symptoms No
Yes
LV EF < 50%
No Yes
Markedly calcified valve and increase in peak jet velocity ≥ 0.3 m/sec within 1 year
No Yes
Patient physically active
Yes
Exercise test No Re-evaluate in 6 to 12 months or when symptoms occur
Normal
Abnormal Surgery
Guidelines ESC,2007
PARA DISMINUIR EL RIESGO QUIRURGICO HAY QUE INTENTAR EVITAR LA CIRUGÍA URGENTE
OPTIMIZAR LA VALORACIÓN DEL PACIENTE “ASINTOMÁTICO”
Correcta evaluación de síntomas incipientes BNP Prueba de esfuerzo Progresión rápida EA críticas •
Click to edit Master text st
– Second lev CIRUGIA
– Third level
Unidad de valvulopatias HGUVH Paciente con EA severa sintomática rechazado en sesión medico-quirúrgica Consulta externa específica. Evaluados 146 pts EcoTT o TE si dudas en la medición Anillo aortico>25mm
Anillo aortico<25mm
Reevaluar cirugía convencional Tratamiento médico <27 mm corevalve?
Coronariografía TAC Evaluación geriatrica SESION CLINICA
Transfemoral 32
Transapical
Tto médico
21
20
Mortalidad 5.6%
MERCI, Dr. Cribier!!!!!! • Click to edit Master text styles – Second level
2004
– Third level • Fourth level – Fifth level
Mas de 12.000 pts
partner
2010
• Click to edit Maste